13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858198
Total reported value
$136.2M
$136.2M
27 檔
34.9%
According to the latest 13F quarterly dataset, KVP Capital Advisors, LP managed an equity portfolio of $136.2M at the end of Q4 2025, spanning 27 distinct U.S. exchange-listed positions.
During Q4 2025, KVP Capital Advisors, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 17.20% | -17.32% | EXIT | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 12.24% | +0.22% | — | |
| 3 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 6.40% | -2.41% | — | |
| 4 | ✓ | Jazz Pharmaceuticals PLC | Stock-Other | 5.10% | — | — | |
| 5 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 5.07% | +1.70% | — | |
| 6 | TRVI | Trevi Therapeutics Inc | Stock-Other | 5.02% | +1.98% | — | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 4.80% | -1.25% | — | |
| 8 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 4.48% | +0.60% | — | |
| 9 | IRON | Disc Medicine Inc | Stock-Other | 4.48% | +0.35% | — | |
| 10 | MBX | Mbx Biosciences Inc | Stock-Other | 3.71% | +2.21% | — | |
| 11 | SVRA | Savara Inc | Stock-Other | 3.53% | +0.27% | — | |
| 12 | TVTX | Travere Therapeutics Inc | Stock-Other | 3.36% | -0.39% | — | |
| 13 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 3.19% | +0.84% | — | |
| 14 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 2.88% | — | — | |
| 15 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.67% | -1.49% | EXIT | |
| 16 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.24% | -0.21% | — | |
| 17 | ACHV | Achieve Life Sciences Inc | Stock-Other | 2.22% | +1.20% | — | |
| 18 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.12% | -2.92% | EXIT | |
| 19 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.92% | +0.17% | — | |
| 20 | VERA | Vera Therapeutics Inc | Stock-Other | 1.60% | +0.05% | — | |
| 21 | ✓ | Fulcrum Therapeutics Inc | Stock-Other | 1.21% | — | — | |
| 22 | IMMX | Immix Biopharma Inc | Stock-Other | 1.17% | +0.17% | — | |
| 23 | NKTR | Nektar Therapeutics | Stock-Other | 1.10% | -0.07% | — | |
| 24 | CABA | Cabaletta Bio Inc | Stock-Other | 1.07% | +0.13% | — | |
| 25 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.55% | — | — | |
| 26 | CELC | Celcuity Inc | Stock-Other | 0.39% | -0.03% | — | |
| 27 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.28% | +0.02% | — |
According to official SEC Form 13F filings, KVP Capital Advisors, LP reported a total U.S. public equity portfolio value of $136.2M across 27 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 430, PRAX, AXSM) accounted for 34.9% of total reported equity market value during Q4 2025.
During Q4 2025, KVP Capital Advisors, LP's top holdings by market value included 430 (17.2%)、PRAX (12.2%)、AXSM (6.4%). The largest single position, 430, represented 17.2% of total portfolio value.
In Q4 2025, KVP Capital Advisors, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.